[go: up one dir, main page]

MX2007005159A - Derivados de pirimidina biciclicos inhibidores del vih. - Google Patents

Derivados de pirimidina biciclicos inhibidores del vih.

Info

Publication number
MX2007005159A
MX2007005159A MX2007005159A MX2007005159A MX2007005159A MX 2007005159 A MX2007005159 A MX 2007005159A MX 2007005159 A MX2007005159 A MX 2007005159A MX 2007005159 A MX2007005159 A MX 2007005159A MX 2007005159 A MX2007005159 A MX 2007005159A
Authority
MX
Mexico
Prior art keywords
substituted
6alkyl
amino
optionally substituted
6alkyloxy
Prior art date
Application number
MX2007005159A
Other languages
English (en)
Inventor
Jan Heeres
Paulus Joannes Lewi
Jerome Emile Georges Guillemont
Paul Adriaan Jan Janssen
Mikael Paugam
Bruno Francois Marie Delest
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of MX2007005159A publication Critical patent/MX2007005159A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Inhibidores de replicacion del VIH de formula (ve formula) N-oxidos, sales de adicion farmaceuticamente aceptables, aminas cuaternarias o sus formas estereoisomericas, en los cuales -a1=a2-a3=a4-es -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N, -N=N-CH=CH-; -b1=b2-b3=b4- es -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N, -N=N-CH=CH-; n y m es 0, 1, 2, 3 y en ciertos casos tambien 4,R1 es hidrogeno; arilo, formilo, alquilcarbonilo C1-6; alquilo C1-6 sustituido en forma opcional; alquiloxicarbonilo C1-6; R2 es OH; halogeno; alquilo C1-6 sustituido en forma opcional, alquenilo C2-6 o alquinilo C2-6; carbonilo sustituido; carboxilo; CN; nitro; amino; amino sustituido; polihalogenometilo; polihalogenometiltio; -S(=O)PR6, C(=NH)R6; R2a es CN; amino, amino sustituido, alquilo C1-6 sustituido en forma opcional; halogeno; alcoxi C1-6 sustituido en forma opcional; carbonilo sustituido; -CH=N-NH-C(=O)-R16; alquiloxi C1-6 sustituido en forma opcional; alquenilo C2-6 sustituido o alquinilo C2-6; -C(=N-O-R8)-alquilo C1-4; R7 o -X-R7; R3 es CN; amino; alquilo C1-6; halogeno; alquiloxi C1-6 sustituido en forma opcional; carbonilo sustituido; -CH=N-NH-C(=O)-R16; alquilo C1-6 sustituido; alquiloxi C1-6 alquilo C1-6 sustituido en forma opcional; alquenilo C2-6 sustituido o alquinilo C2-6; -C(=N-O-R8)-alquilo C1-4; R7; R4 es halogeno; OH; alquilo C1-6 sustituido en forma opcional, alquenilo C2-6 o alquinilo C2-6; cicloalquilo C3-7; alquiloxi C1-6; CON; nitro; polihalogenoalquilo C1-6; polihalogenoalquiloxi C1-6; carbonilo sustituido; formilo; amino; mono- o di(alquil C1-4-)amino o R7; -A-B- es -CR5=N-, -N=N-, -CH2-CH2-, -CS-NH-, -CO-NH-, -CH=CH-; composiciones farmaceuticas que los comprenden; metodos para la preparacion de estos compuestos y estas composiciones; el uso de estos compuestos para la prevencion o el tratamiento de la infeccion por VIH.
MX2007005159A 2004-10-29 2005-10-27 Derivados de pirimidina biciclicos inhibidores del vih. MX2007005159A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105419 2004-10-29
PCT/EP2005/055589 WO2006045828A1 (en) 2004-10-29 2005-10-27 Hiv inhibiting bicyclic pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2007005159A true MX2007005159A (es) 2007-06-26

Family

ID=34929789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005159A MX2007005159A (es) 2004-10-29 2005-10-27 Derivados de pirimidina biciclicos inhibidores del vih.

Country Status (16)

Country Link
US (5) US8153640B2 (es)
EP (1) EP1807430B1 (es)
JP (1) JP5118972B2 (es)
KR (1) KR20070085286A (es)
CN (1) CN101048410B (es)
AR (1) AR051410A1 (es)
AU (1) AU2005298637B8 (es)
BR (1) BRPI0517272A (es)
CA (1) CA2577588C (es)
ES (1) ES2508766T3 (es)
IL (1) IL180963A (es)
MX (1) MX2007005159A (es)
RU (1) RU2403254C2 (es)
TW (1) TW200630370A (es)
WO (1) WO2006045828A1 (es)
ZA (1) ZA200703444B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2006122003A2 (en) 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
ZA200807715B (en) * 2006-03-09 2009-11-25 Pharmacopeia Inc 9-Heteroarylpurine MNK2 inhibitors for treating metabolic disorders
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
KR20140104060A (ko) 2006-10-19 2014-08-27 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
US20110046131A1 (en) * 2006-10-20 2011-02-24 N.V. Organon and Pharmacopeia, LLC Purines as pkc-theta inhibitors
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
EP2220091B1 (en) 2007-12-14 2012-07-25 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
AU2009211338B2 (en) * 2008-02-06 2011-12-15 Novartis Ag Pyrrolo[2, 3-D] pyrimidines and use thereof as tyrosine kinase inhibitors
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
MY177695A (en) 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
CN102115452A (zh) * 2009-12-30 2011-07-06 上海特化医药科技有限公司 (e)-3-(3-取代-5-甲基苯基)丙烯腈及其制备方法
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011135578A1 (en) 2010-04-28 2011-11-03 Chetan Balar Composition comprising chitin and tinosporin for use in the treatment of viral diseases
WO2013059396A2 (en) 2011-10-19 2013-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
MX363034B (es) 2011-12-02 2019-03-06 Signal Pharm Llc Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida de las mismas y metodos de su uso.
CN104066734B (zh) * 2012-01-28 2017-03-29 默克专利股份公司 三唑并[4,5‑d]嘧啶衍生物
EA028462B1 (ru) 2012-02-24 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor
ES2664094T3 (es) 2012-07-12 2018-04-18 Hetero Research Foundation Procedimiento de preparación de rilpivirina utilizando un intermedio nuevo
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
ES2638179T3 (es) 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos
PE20151274A1 (es) 2013-02-08 2015-09-12 Celgene Avilomics Res Inc Inhibidores de erk y sus usos
CA2903901A1 (en) 2013-03-05 2014-09-12 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
JP6382945B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
KR102459285B1 (ko) 2013-04-17 2022-10-27 시그날 파마소티칼 엘엘씨 1-에틸-7-(2-메틸-6-(1H-1,2,4-트리아졸-3-일)피리딘-3-일)-3,4-디하이드로피라지노[2,3-b]피라진-2(1H)-온에 관한 약학 제제, 제조방법, 고체 형태 및 사용 방법
KR102221029B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
TWI654979B (zh) 2013-04-17 2019-04-01 美商標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
WO2014172432A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
EP2994471B1 (en) 2013-05-06 2017-05-17 Merck Patent GmbH Macrocycles as kinase inhibitors
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
PH12019500143B1 (en) 2013-08-23 2023-03-24 Neupharma Inc Certain chemical entities, compositions, and methods
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
JP2017520603A (ja) 2014-07-14 2017-07-27 シグナル ファーマシューティカルズ，エルエルシー 置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016020288A1 (en) 2014-08-04 2016-02-11 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
TW202237569A (zh) * 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
EA032430B1 (ru) 2014-12-24 2019-05-31 Джилид Сайэнс, Инк. Конденсированные пиримидины для лечения вич
BR112017013440A2 (pt) * 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
AU2016220219B2 (en) * 2015-02-17 2020-05-14 Neupharma, Inc. Certain chemical entities, compositions, and methods
HUE057838T2 (hu) 2016-06-07 2022-06-28 Jacobio Pharmaceuticals Co Ltd SHP2 inhibitorokként hasznos új heterociklusos származékok
WO2018035061A1 (en) * 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
TWI664175B (zh) 2017-03-23 2019-07-01 大陸商北京加科思新藥研發有限公司 用於作為shp2抑制劑之新穎雜環衍生物
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
US20210380540A1 (en) * 2018-10-25 2021-12-09 Minakem Process for the preparation of rilpivirine
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
JOP20220160A1 (ar) 2019-12-20 2023-01-30 Nuevolution As مركبات فعّالة نحو مستقبلات نووية
AU2021224460A1 (en) 2020-02-19 2022-12-15 Pharmasyntez, Joint Stock Company Pyrimidine-based bicycles as antiviral agents for the treatment and prevention of HIV infection
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
MX2022012259A (es) 2020-03-31 2022-12-08 Nuevolution As Compuestos activos frente a receptores nucleares.
CN111303162B (zh) * 2020-04-16 2021-01-22 天津法莫西医药科技有限公司 一种2-氯-7-环戊基-7H-吡咯并[2,3-d]嘧啶-6-羧酸的制备方法
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2025143856A1 (ko) * 2023-12-27 2025-07-03 주식회사 에이조스바이오 신규 퓨린계 화합물 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD21593A (es) *
DE21593C (de) Dr. LÖWIG, Prof. in Breslau Verfahren zur Darstellung von Aetznatron und Aetzkali durch Glühen von Strontiumcarbonat oder Kaliumcarbonat mit Eisenoxyd
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
JPS5962594A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５―ジ置換―トリアゾロピリミジン誘導体
CN1198655C (zh) 1995-11-23 2005-04-27 詹森药业有限公司 通过熔体挤出法制备的环糊精固体混合物
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
HU230522B1 (hu) 1998-03-27 2016-10-28 Janssen Pharmaceutica N.V HIV-gátló pirimidinszármazékok
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
HU227453B1 (en) 1998-11-10 2011-06-28 Janssen Pharmaceutica Nv Hiv replication inhibiting pyrimidines, and pharmaceutical compositions containing them
ES2542326T3 (es) 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
MXPA04008592A (es) * 2002-03-07 2004-12-06 Hoffmann La Roche Inhibidores de piridina biciclica y pirimidina p38 cinasa.
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
CN100372851C (zh) 2003-05-05 2008-03-05 弗·哈夫曼-拉罗切有限公司 具有crf活性的稠合的嘧啶衍生物
US7449465B2 (en) 2003-07-16 2008-11-11 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
BRPI0412596A (pt) * 2003-07-16 2006-09-19 Janssen Pharmaceutica Nv derivados de triazolopirimidina como inibores de glicogênio sintase cinase 3
DK1713806T3 (da) * 2004-02-14 2013-08-05 Irm Llc Forbindelser og sammensætninger som proteinkinaseinhibitorer
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation

Also Published As

Publication number Publication date
ES2508766T3 (es) 2014-10-16
IL180963A (en) 2015-06-30
US9487518B2 (en) 2016-11-08
CN101048410B (zh) 2010-06-23
US9802943B2 (en) 2017-10-31
CA2577588C (en) 2013-09-10
IL180963A0 (en) 2007-07-04
ZA200703444B (en) 2008-11-26
WO2006045828A1 (en) 2006-05-04
US20120190697A1 (en) 2012-07-26
US8153640B2 (en) 2012-04-10
AU2005298637A1 (en) 2006-05-04
BRPI0517272A (pt) 2008-10-07
RU2007119784A (ru) 2008-12-10
AR051410A1 (es) 2007-01-10
TW200630370A (en) 2006-09-01
EP1807430B1 (en) 2014-07-23
US10077270B2 (en) 2018-09-18
CA2577588A1 (en) 2006-05-04
AU2005298637B8 (en) 2012-12-06
JP5118972B2 (ja) 2013-01-16
CN101048410A (zh) 2007-10-03
RU2403254C2 (ru) 2010-11-10
AU2005298637A8 (en) 2012-12-06
KR20070085286A (ko) 2007-08-27
AU2005298637B2 (en) 2012-06-28
JP2008517978A (ja) 2008-05-29
US20160355519A1 (en) 2016-12-08
US10072015B2 (en) 2018-09-11
EP1807430A1 (en) 2007-07-18
US20180009819A1 (en) 2018-01-11
US20180016281A1 (en) 2018-01-18
US20080085907A1 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
MX2007005159A (es) Derivados de pirimidina biciclicos inhibidores del vih.
TW200626560A (en) HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines
TW200626574A (en) HIV inhibiting 5-heterocyclyl pyrimidines
AP1610A (en) HIV replication inhibiting pyrimidines.
PL378064A1 (pl) Pirymidyny i triazyny hamujące replikację wirusa HIV
MY176490A (en) Pyrimidine derivatives for the prevention of hiv infection
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
BR0213522B1 (pt) compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto
CA2473864A1 (en) Composition for use in treating patients suffering from movement disorder
NO20073405L (no) Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning
MXPA06000300A (es) Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de gonadotropina.
UA85541C2 (ru) Карбаматные производные хинуклидина и фармацевтическая композиции, которая содержит эти соединения
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2004094431A3 (en) 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200744595A (en) Quinoline derivatives as antibacterial agents
TW200626561A (en) HIV inhibiting 5-substituted pyrimidines
TW200504030A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MY138996A (en) 4-amino-5-cyanopyrimidine derivatives
DE69315307D1 (de) Chimuclidine Derivate als Squalen synthetase Inhibitoren
TH83894A (th) พิริมิดีนที่ถูกแทนที่ด้วย 5-คาร์โบ-หรือเฮเทอโรไซคลิคที่ยับยั้ง hiv
TH79598A (th) อนุพันธ์ของไบไซคลิคพิริมิดีนซึ่งยับยั้งเอชไอวี
TW200628155A (en) HIV replication inhibiting pyrimidines
SE0102867D0 (sv) Non-nucleoside reverse transcriptase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration